APA (7th ed.) Citation

E, T., PT, M., K, P., F, B., M, B., S, S. B., . . . GA, K. (2022). Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA neurology, 79(8), 758. https://doi.org/10.1001/jamaneurol.2022.1375

Chicago Style (17th ed.) Citation

E, Teng, et al. "Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial." JAMA Neurology 79, no. 8 (2022): 758. https://doi.org/10.1001/jamaneurol.2022.1375.

MLA (9th ed.) Citation

E, Teng, et al. "Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial." JAMA Neurology, vol. 79, no. 8, 2022, p. 758, https://doi.org/10.1001/jamaneurol.2022.1375.